Navigation Links
Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
Date:5/2/2013

PITTSBURGH, May 2, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months ended March 31, 2013.

Financial Highlights

  • Adjusted diluted EPS of $0.62 for the three months ended March 31, 2013 compared to $0.52 for the same prior year period, an increase of 19%
  • Total revenues of $1.63 billion for the three months ended March 31, 2013 compared to $1.58 billion for the same prior year period, an increase of 3%
  • On a GAAP basis, diluted EPS of $0.27 for the three months ended March 31, 2013 compared to $0.30 for the same prior year period, a decrease of 10% (the 2013 first quarter included pretax expenses related to research and development licensing payments of $23 million and acquisition related costs of $19 million, reducing GAAP diluted EPS by a total of approximately $0.08)
  • Adjusted operating cash flow of $90 million for the three months ended March 31, 2013, an increase of 30%  compared to the same prior year period
  • On a GAAP basis, cash flow from operating activities of $88 million for the three months ended March 31, 2013, an increase of $195 million compared to the same prior year period
  • Completed the repurchase of approximately 16.3 million shares of common stock for approximately $500 million during the three months ended March 31, 2013
  • Mylan Chief Executive Officer, Heather Bresch commented: "Our first quarter results provide a strong start to the year and are fully in line with our expectations. We generated double-digit, constant currency top-line growth in our European and Asia Pacific regions, and saw strong performance in our North American business. I am also very pleased with the performance of our Specialty segment, particularly our EpiPen® Auto-Injector franchise, which celebrates its 25th anniversary this year and co
    '/>"/>

    SOURCE Mylan Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Mylan Launches Generic Version of Zyprexa® Tablets
    2. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
    3. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
    4. Mylan Launches Generic Lipitor® in Five European Countries
    5. Mylan Launches Generic Version of Plavix® Tablets
    6. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
    7. Mylan Launches Generic Version of Viramune® Tablets
    8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
    9. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
    10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
    11. Mylan Launches Generic Version of Lipitor®
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... 2014 Research and Markets has ... Aseptic Packaging Industry Report 2014" report to their ... The Global and Chinese Aseptic Packaging Industry Report ... state of the global Aseptic Packaging industry with a ... a basic overview of the industry including definitions, classifications, ...
    (Date:7/30/2014)... N.J. , July 30, 2014  InnoPharma, Inc. ... Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in ... agitation and disturbed behaviors in patients with schizophrenia or ... this generic injectable drug, InnoPharma has entered into an ... Sandoz Canada will make, use, sell, market and ...
    (Date:7/30/2014)... and KISSING, Germany , July 30, ... a single use and computer-assisted ("robotic") colonoscopy system, today ... a worldwide recognized medical device executive, as a new ... Shamir is a highly respected global visionary in the ... served as President and Chief Executive Officer at Given ...
    Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3
    ... Isis Pharmaceuticals,Inc. (Nasdaq: ISIS ) announced ... from a randomized Phase 2 clinical trial of,OGX-011 ... arm"),compared to docetaxel and prednisone alone ("the control ... cancer. The current 10.6,month median overall survival ...
    ... DIEGO, Dec. 3 Vical Incorporated,(Nasdaq: VICL ... with EIP,Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and ... and the Turkish,Republic of Northern Cyprus. EIP has agreed ... to pay Vical upfront and milestone payments,plus a specified ...
    Cached Medicine Technology:Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5
    (Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
    (Date:7/30/2014)... Orange, NJ. July 30, 2014. A new network of ... NIH Stroke Trials Network (NIH StrokeNet) is working ... the U.S. Despite advances of the last two ... year, stroke causes death or disability for 795,000 Americans. ... aging of the population. , To accelerate the ...
    (Date:7/30/2014)... 30, 2014 The Technology Association of ... of TAG (B&TA), today issued its final call for ... , Interested companies have until August 29th 2014 to ... will be selected by the Excalibur Judging Committee. Companies ... with the judges for interviewing process. , The ...
    (Date:7/30/2014)... July 30, 2014 Over 630 doctors ... Surgical Technique®, the revolutionary minimally invasive treatment for gum ... by many of his peers to be the “father ... at a recent Chao Pinhole Surgical Technique® training course ... Shanelec is the recipient of the American Academy of ...
    (Date:7/30/2014)... July 30, 2014 As the controversy ... in gynecological surgeries continues to grow, Bernstein Liebhard LLP ... those calling for a ban on uterine morcellation. According ... was diagnosed with leiomyosarcoma following a hysterectomy that involved ... of her diagnosis, the aggressive cancer had progressed to ...
    Breaking Medicine News(10 mins):Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
    ... a greater risk of suffering from overweight and obesity. This ... children examined on starting school. Elisabeth Weber and her coauthors ... rzteblatt International ( Dtsch Arztbl Int 2008; 105 ... weight, and height of the children, but also their mother ...
    ... they behave like engineering parts is the focus of research ... 8 million grant from the Engineering and Physical Sciences Research ... synthetic biology. This is a field in which engineers work ... These parts could be used to build biological devices that ...
    ... want it must give up aggressive treatments, researchers say ... with life-threatening illnesses would seek hospice care if Medicare ... give up aggressive treatment of their ailments, a new ... but the issue was one of money, not race, ...
    ... is now open. The auction will run from December 18, ... Nick Foundation, Inc, a charity dedicated to male breast cancer awareness ... timeshares to donated items guaranteed to delight and surprise. Tell your ... ...
    ... Ride Home Program on New Year,s Eve , ... Terre Haute, Ind. (PRWEB) December 22, ... Yellow Cab of Terre Haute to provide free transportation to those who can,t ... Eve. The Safe and Sober Free Cab Ride Home program will be available ...
    ... -- A new study finds that hospice servicescare that ... aides, social workers and counselorshave restrictions that reduce usage ... Americans. The research, published in the February 1, 2009 ... the American Cancer Society, indicates that the eligibility criteria ...
    Cached Medicine News:Health News:New center launched today to spearhead UK research in synthetic biology 2Health News:New center launched today to spearhead UK research in synthetic biology 3Health News:Rules Change Could Increase Hospice Use 2Health News:Holiday Online Auction - Dedicated to Awareness of Male Breast Cancer - Hosted by John W. Nick Foundation, Inc. at MaleBreastCancer.org 2Health News:Fleschner, Stark, Tanoos & Newlin to Offer Free Terre Haute Cab Rides on New Year's Eve 2Health News:Fleschner, Stark, Tanoos & Newlin to Offer Free Terre Haute Cab Rides on New Year's Eve 3Health News:Eligibility criteria contribute to racial disparities in hospice use 2
    ... interventional cardiology, accurate lesion assessment ... in determining the appropriate stent ... Cardiac 3-D (IC3D), a highly ... clinicians are now able to ...
    ... versatile solution designed to optimize the workflow ... to diagnosis and therapy, for both diagnostic ... your cath lab becomes an integral part ... free to concentrate on what really matters: ...
    ... FC is a floor-mounted, single ... system architecture for vascular and ... flexible and ergonomic system architecture ... the system configuration to focus ...
    The ACUSON Sequoia C512 system elevates imaging and Doppler performance through new, high-density acoustic sampling, precise control of the transmitted acoustic waveform, and new transducer technolog...
    Medicine Products: